Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: December 15, 2011
Last updated: December 22, 2011
Last verified: December 2011

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in tumor samples from younger patients with neuroblastoma.

Condition Intervention
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: mutation analysis
Genetic: protein analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: microscopy

Study Type: Observational
Official Title: Proposed Studies on the Role of Growth Factor Receptor Trafficking in Neuroblastoma Pathogenesis

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Expression of UBE4B, hrs, and members of the ubiquitination protein complex [ Designated as safety issue: No ]
  • Expression levels and cellular localization of the UBE4B, hrs, and growth factor receptors [ Designated as safety issue: No ]
  • 1p36 deletion status and its association with UBE4B [ Designated as safety issue: No ]

Estimated Enrollment: 5
Study Start Date: December 2011
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Detailed Description:


  • To determine the expression of UBE4B, hrs, and members of the ubiquitination protein complex in previously banked primary neuroblastoma tumor samples from the Children's Oncology Group.
  • To determine the correlation of expression levels and cellular localization of the UBE4B and hrs proteins with growth factor-receptor tumor cell-surface expression.
  • To determine the 1p36 deletion status by fluorescence in situ hybridization (FISH) analysis and their association with expression levels of UBE4B and hrs in previously banked primary neuroblastoma tumor samples from the Children's Oncology Group.

OUTLINE: Banked tumor tissue samples are analyzed for expression of UBE4B, hrs, members of the ubiquitination protein complex, growth factor receptors, and 1p36 deletion status by immunohistochemistry (IHC), fluorescent microscopy, and fluorescence in situ hybridization (FISH).


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Tumor tissue microarrays from the Children's Oncology Group neuroblastoma tumor bank


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01493830

Sponsors and Collaborators
Children's Oncology Group
Principal Investigator: Peter Zage, MD, PhD Texas Children's Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office Identifier: NCT01493830     History of Changes
Other Study ID Numbers: CDR0000719951, COG-ANBL12B4
Study First Received: December 15, 2011
Last Updated: December 22, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral processed this record on March 26, 2015